| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 5th, 2005 | 16 | No |
Popular Name: DNC007764 DNC007764
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 2.29 | -1.33 | -9.91 | 2 | 3 | 0 | 49 | 210.236 | 1 | ↓ |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| AKT1-2-E | RAC-alpha Serine/threonine-protein Kinase (cluster #2 Of 3), Eukaryotic | Eukaryotes | 3000 | 0.48 | Binding ≤ 10μM |
| FLT3-1-E | Tyrosine-protein Kinase Receptor FLT3 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 350 | 0.56 | Binding ≤ 10μM |
| JAK3-1-E | Tyrosine-protein Kinase JAK3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 900 | 0.53 | Binding ≤ 10μM |
| PDPK1-1-E | 3-phosphoinositide Dependent Protein Kinase-1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 520 | 0.55 | Binding ≤ 10μM |
| RET-1-E | Tyrosine-protein Kinase Receptor RET (cluster #1 Of 1), Eukaryotic | Eukaryotes | 460 | 0.55 | Binding ≤ 10μM |
| SRPK1-1-E | Serine/threonine-protein Kinase SRPK1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 361 | 0.56 | Binding ≤ 10μM |
| ST17B-1-E | Serine/threonine-protein Kinase 17B (cluster #1 Of 1), Eukaryotic | Eukaryotes | 353 | 0.56 | Binding ≤ 10μM |
| VGFR1-1-E | Vascular Endothelial Growth Factor Receptor 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 390 | 0.56 | Binding ≤ 10μM |
| VGFR2-1-E | Vascular Endothelial Growth Factor Receptor 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 140 | 0.60 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| PDPK1_HUMAN | O15530 | 3-phosphoinositide Dependent Protein Kinase-1, Human | 520 | 0.55 | Binding ≤ 1μM |
| ST17B_HUMAN | O94768 | Serine/threonine-protein Kinase 17B, Human | 353 | 0.56 | Binding ≤ 1μM |
| SRPK1_HUMAN | Q96SB4 | Serine/threonine-protein Kinase SRPK1, Human | 361 | 0.56 | Binding ≤ 1μM |
| JAK3_HUMAN | P52333 | Tyrosine-protein Kinase JAK3, Human | 900 | 0.53 | Binding ≤ 1μM |
| FLT3_HUMAN | P36888 | Tyrosine-protein Kinase Receptor FLT3, Human | 350 | 0.56 | Binding ≤ 1μM |
| RET_HUMAN | P07949 | Tyrosine-protein Kinase Receptor RET, Human | 460 | 0.55 | Binding ≤ 1μM |
| VGFR1_MOUSE | P35969 | Vascular Endothelial Growth Factor Receptor 1, Mouse | 390 | 0.56 | Binding ≤ 1μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 140 | 0.60 | Binding ≤ 1μM |
| PDPK1_HUMAN | O15530 | 3-phosphoinositide Dependent Protein Kinase-1, Human | 1800 | 0.50 | Binding ≤ 10μM |
| ST17B_HUMAN | O94768 | Serine/threonine-protein Kinase 17B, Human | 353 | 0.56 | Binding ≤ 10μM |
| AKT1_HUMAN | P31749 | Serine/threonine-protein Kinase AKT, Human | 2300 | 0.49 | Binding ≤ 10μM |
| SRPK1_HUMAN | Q96SB4 | Serine/threonine-protein Kinase SRPK1, Human | 361 | 0.56 | Binding ≤ 10μM |
| JAK3_HUMAN | P52333 | Tyrosine-protein Kinase JAK3, Human | 900 | 0.53 | Binding ≤ 10μM |
| FLT3_HUMAN | P36888 | Tyrosine-protein Kinase Receptor FLT3, Human | 350 | 0.56 | Binding ≤ 10μM |
| RET_HUMAN | P07949 | Tyrosine-protein Kinase Receptor RET, Human | 460 | 0.55 | Binding ≤ 10μM |
| VGFR1_MOUSE | P35969 | Vascular Endothelial Growth Factor Receptor 1, Mouse | 390 | 0.56 | Binding ≤ 10μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 140 | 0.60 | Binding ≤ 10μM |
| Description | Species |
|---|---|
| Activation of BAD and translocation to mitochondria | |
| Activation of PKB | |
| AKT phosphorylates targets in the cytosol | |
| AKT phosphorylates targets in the nucleus | |
| AKT-mediated inactivation of FOXO1A | |
| Butyrate Response Factor 1 (BRF1) destabilizes mRNA | |
| CD28 dependent PI3K/Akt signaling | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| CTLA4 inhibitory signaling | |
| deactivation of the beta-catenin transactivating complex | |
| Downregulation of ERBB2:ERBB3 signaling | |
| Downstream TCR signaling | |
| eNOS activation | |
| EPHA-mediated growth cone collapse | |
| FCERI mediated NF-kB activation | |
| G beta:gamma signalling through PI3Kgamma | |
| GPVI-mediated activation cascade | |
| Integrin alphaIIb beta3 signaling | |
| Integrin cell surface interactions | |
| Interleukin receptor SHC signaling | |
| Interleukin-2 signaling | |
| Interleukin-7 signaling | |
| KSRP destabilizes mRNA | |
| Negative regulation of the PI3K/AKT network | |
| Neurophilin interactions with VEGF and VEGFR | |
| PIP3 activates AKT signaling | |
| Role of LAT2/NTAL/LAB on calcium mobilization | |
| RSK activation | |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |
| Translocation of GLUT4 to the plasma membrane | |
| VEGF binds to VEGFR leading to receptor dimerization | |
| VEGFA-VEGFR2 Pathway | |
| VEGFR2 mediated cell proliferation | |
| VEGFR2 mediated vascular permeability |
